For the quarter ended December 2025, LivaNova (LIVN) reported revenue of $360.9 million, up 12.2% over the same period last year. EPS came in at $0.86, compared to $0.81 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $350.93 million, representing a surprise of +2.84%. The company delivered an EPS surprise of +7.06%, with the consensus EPS estimate being $0.80.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...

Key Takeaways Stryker launched Synchfix EVT, a next-gen flexible fixation system for ankle syndesmotic injuries.SYK's device simplifies deployment, supports single-handed use and improves OR efficiency.Stryker's system is first approved for adolescents, expanding reach in ankle trauma care.Stryker (SYK) recently expanded its trauma portfolio with the launch of Synchfix EVT, a next-generation flexible syndesmotic fixation system to improve procedural efficiency and maintain effective ankle stabilization in p ...

1,826,519$ 1,533,181Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable$ 34,736$ 31,326Accrued liabilities132,163112,429Current operating lease liabilities13,84112,221Current finance lease liabilities2,3932,369Total current liabilities183,133158,345Non-current operating lease liabilities182,751187,068Non-current finance lease liabilities20,71421,731Other non-current liabilities12,31815,106Total liabilities398,916382,250Stockholders' equity:Preferred stock——Common stock3938Additional pai ...

BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Beta Bionics, Inc. (Nasdaq: BBNX) for potential securities law violations. Investors who have lost money in their Beta Bionics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/bbnx. What is this all about? Shares of Beta Bionics fell over 35% in January, after the company released preliminary Q4 2025 topline results showing new pat ...

Key Takeaways TMDX reported Q4 EPS of 57 cents, up 200% year over year, beating estimates by 39%.TransMedics posted 32% revenue growth in Q4, driven by the Organ Care System and logistics expansion.TMDX sees 2026 revenues of $727M-$757M, implying 20-25% growth over 2025 levels.TransMedics Group (TMDX) delivered earnings per share (EPS) of 57 cents in the fourth quarter of 2025, excluding a one-time benefit related to deferred tax assets, which surged 200% year over year. The figure surpassed the Zacks Conse ...

Performance in 2025 was characterized by the third consecutive year of double-digit organic revenue growth, driven by the Essence heart-lung machine (HLM) rollout and market share gains in cardiopulmonary consumables. The cardiopulmonary segment's growth is being fueled by a global upgrade cycle, with Essence representing 55% of HLM units in 2025 and targeted to reach 80% of new placements by 2026. Management attributed epilepsy growth to strong commercial execution and the impact of the CORE VNS stud ...

Achieved record performance in Q4 2025, validating management's view that Q3 seasonality was transient and that the U.S. transplant market would recover in the final quarter. Demonstrated market expansion rather than just share-taking, with data showing U.S. liver, heart, and lung volumes grew 25% since 2022 with OCS NOP, but would have declined 1% without it. Attributed strong liver performance to clinical leadership and execution excellence, with OCS Liver now representing 36% of the total U.S. live ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Sco ...

Thermo Fisher Scientific Inc. (TMO) is a leading life sciences and technology company that develops and supplies scientific instruments, laboratory equipment, specialty diagnostics, reagents, and biopharmaceutical services used across research, healthcare, and industrial markets worldwide. The company is headquartered in Waltham, Massachusetts, and is growing rapidly through acquisitions and innovation in analytical technologies and laboratory services. Thermo Fisher Scientific’s market cap is around $193. ...

Wall Street analysts forecast that Dentsply International (XRAY) will report quarterly earnings of $0.28 per share in its upcoming release, pointing to a year-over-year increase of 7.7%. It is anticipated that revenues will amount to $920.05 million, exhibiting an increase of 1.7% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated thei ...